Skip to main content
Fig. 8 | Molecular Cancer

Fig. 8

From: KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges

Fig. 8

Some studies find that KDM5 proteins may inhibit breast cancer progression. AKT-catalyzed phosphorylation of KDM5A restricts the access of KDM5A to the nucleus, and KDM5A in the nucleus inhibits the expression of proteins related to the cell cycle, mitosis, and DNA replication by decreasing methylation on TSS H3K4. KDM5B localizes to the promoters of ITGA6 and ITGB1 along with the SIN3A complex to repress their expression thereby inhibiting breast cancer invasion. Moreover, KDM5B promotes the stemness phenotype of breast cancer cells by suppressing the expression of the cell stemness genes Sox2 and Nanog. RACK7 localizes to oncogenes with EZH2 and KDM5C to inhibit their expression by regulating histone bivalent modifications thereby suppressing cell stemness, drug resistance, and EMT

Back to article page

Molecular Cancer

ISSN: 1476-4598